AQR Capital Administration LLC boosted its stake in Takeda Pharmaceutical Firm Restricted (NYSE:TAK – Free Report) by 153.7% in the course of the second quarter, in response to its most up-to-date Type 13F submitting with the Securities and Change Fee (SEC). The institutional investor owned 90,013 shares of the corporate’s inventory after buying a further 54,539 shares in the course of the quarter. AQR Capital Administration LLC’s holdings in Takeda Pharmaceutical have been price $1,165,000 as of its most up-to-date submitting with the Securities and Change Fee (SEC).
A number of different hedge funds have additionally purchased and offered shares of the inventory. Rise Advisors LLC bought a brand new stake in shares of Takeda Pharmaceutical in the course of the 1st quarter valued at $26,000. GAMMA Investing LLC raised its place in Takeda Pharmaceutical by 50.9% in the course of the first quarter. GAMMA Investing LLC now owns 2,864 shares of the corporate’s inventory valued at $40,000 after buying a further 966 shares within the final quarter. EverSource Wealth Advisors LLC boosted its holdings in shares of Takeda Pharmaceutical by 38.6% within the 2nd quarter. EverSource Wealth Advisors LLC now owns 3,082 shares of the corporate’s inventory price $43,000 after buying a further 859 shares within the final quarter. Headlands Applied sciences LLC purchased a brand new place in shares of Takeda Pharmaceutical in the course of the 2nd quarter valued at about $59,000. Lastly, Blue Belief Inc. raised its holdings in shares of Takeda Pharmaceutical by 74.0% in the course of the 2nd quarter. Blue Belief Inc. now owns 5,480 shares of the corporate’s inventory valued at $76,000 after shopping for a further 2,330 shares within the final quarter. 9.17% of the inventory is at the moment owned by institutional buyers.
Takeda Pharmaceutical Inventory Efficiency
NYSE:TAK opened at $14.30 on Friday. Takeda Pharmaceutical Firm Restricted has a 1-year low of $12.57 and a 1-year excessive of $15.39. The corporate has a debt-to-equity ratio of 0.65, a present ratio of 1.26 and a fast ratio of 0.74. The enterprise has a 50 day transferring common of $14.56 and a 200 day transferring common of $13.75. The corporate has a market capitalization of $45.48 billion, a price-to-earnings ratio of 26.97, a PEG ratio of 0.27 and a beta of 0.54.
Takeda Pharmaceutical (NYSE:TAK – Get Free Report) final introduced its quarterly earnings information on Wednesday, July thirty first. The corporate reported $0.56 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.37 by $0.19. Takeda Pharmaceutical had a internet margin of 6.02% and a return on fairness of 10.11%. The corporate had income of $7.75 billion in the course of the quarter. On common, sell-side analysts predict that Takeda Pharmaceutical Firm Restricted will submit 1.58 earnings per share for the present fiscal yr.
Takeda Pharmaceutical Profile
Takeda Pharmaceutical Firm Restricted engages within the analysis, improvement, manufacture, advertising, and out-licensing of pharmaceutical merchandise in Japan and internationally. It presents pharmaceutical merchandise within the areas of gastroenterology, uncommon ailments, plasma derived therapies, immunology, oncology, and neuroscience.
Really useful Tales
Wish to see what different hedge funds are holding TAK? Go to HoldingsChannel.com to get the newest 13F filings and insider trades for Takeda Pharmaceutical Firm Restricted (NYSE:TAK – Free Report).
Obtain Information & Rankings for Takeda Pharmaceutical Every day – Enter your electronic mail deal with beneath to obtain a concise each day abstract of the newest information and analysts’ rankings for Takeda Pharmaceutical and associated corporations with MarketBeat.com’s FREE each day electronic mail publication.